Press releases

10
Nov 2022
07:30 E.S.T.

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

Read more
3
Nov 2022
20:05 E.S.T.

Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

Read more
3
Nov 2022
17:43 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022

Read more
27
Oct 2022
20:30 E.S.T.

Cellectis to Report Third Quarter 2022 Financial Results

Read more
11
Oct 2022
20:30 E.S.T.

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Read more
5
Oct 2022
20:30 E.S.T.

Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Read more
28
Sep 2022
20:25 E.S.T.

Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

Read more
1
Sep 2022
20:30 E.S.T.

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

Read more
4
Aug 2022
20:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

Read more
1
Aug 2022
20:30 E.S.T.

Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US